Fund Managers
PersonRelationship Network
Event Timeline
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
Management Company
|
Employment affiliation |
5
|
1 | |
|
organization
Folio
|
Governance ownership |
5
|
1 | |
|
organization
NLV-III
|
Management |
5
|
1 | |
|
person
Academic Thought Leaders
|
Professional network |
5
|
1 | |
|
person
venture capitalists
|
Business associate |
5
|
1 | |
|
organization
Sprout
|
Management |
5
|
1 | |
|
organization
New Leaf
|
Management |
1
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| N/A | N/A | Major investor, medical and scientific meetings | Various | View |
| 2021-04-06 | N/A | Victim had interview with Epstein Victims Compensation Fund managers. | Unknown | View |
| 2021-04-06 | N/A | Client interview with Epstein Victims Compensation Fund managers. | Unknown | View |
| 2008-01-01 | N/A | NLV-I completed its new investment period | N/A | View |
| 2008-01-01 | N/A | NLV-II Fund Managers began investing | N/A | View |
| 2005-06-01 | N/A | NLV-I Fund Managers began investing | N/A | View |
HOUSE_OVERSIGHT_024055.jpg
This document appears to be a page from an investment memorandum for 'NLV-III' (New Leaf Ventures III). It outlines the 'New Leaf' team's due diligence process, risk assessment factors (such as IP strength and regulatory risks), and team-oriented management philosophy. It also details the intended portfolio composition, targeting 24-28 companies with a specific asset allocation focused heavily on biopharmaceuticals (50-60%).
HOUSE_OVERSIGHT_024054.jpg
This document is page 43 of a confidential investment memorandum describing the 'Deal Sourcing & Investment Process' for a fund referred to as 'NLV'. It details the Fund Managers' strategy of tracking biopharma companies (specifically in Oncology, Infectious Disease, and CNS) and leveraging a high-level network of industry executives and scientists to identify investment opportunities. The page bears a House Oversight Bates stamp, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024053.jpg
This document is page 42 of a confidential investment strategy memorandum for NLV-III (New Leaf Ventures III). It details the strategy for investing in 'Biological Research Tools & Infrastructure,' highlighting the benefits of lower regulatory risks compared to biopharma and aiming for companies near the commercial stage. The document notes that up to 15% of the fund will be allocated to this sector and medical devices, citing 'Advanced Cellular Diagnostics' from the previous NLV-II fund as a successful example.
HOUSE_OVERSIGHT_024052.jpg
This document appears to be page 41 of a confidential investment memorandum for 'New Leaf,' specifically regarding their third fund, NLV-III. It outlines the 'Medical Devices Investment Strategy,' emphasizing a shift toward later-stage opportunities due to regulatory headwinds in the U.S. and E.U. The document cites specific portfolio successes like Neuronetics, CardioKinetix, and the acquisition of Interlace Medical by Hologix to demonstrate the team's track record.
HOUSE_OVERSIGHT_024051.jpg
This document is a page from a confidential investment memorandum (Control Number 257) produced for the House Oversight Committee. It details the investment strategy for 'NLV-III' (New Leaf Ventures III), focusing on healthcare themes like patient engagement and cost transparency, citing past successes with companies like Audax Health and Truveris. The text outlines the fund's strategy to invest in U.S. private companies, take significant ownership positions, and leverage board participation.
HOUSE_OVERSIGHT_024050.jpg
This document is page 39 of a confidential investment memorandum or fund report stamped by House Oversight. It details specific healthcare investment themes including Care Coordination, Clinical Error Reduction, and Analytics/Data-Driven Personalization, highlighting portfolio companies such as TigerText, ePocrates, iRhythm Technologies, and Treato. The document notes the financial success of ePocrates (acquired for $293 million) and attributes several companies to a fund designated as 'NLV-II'.
HOUSE_OVERSIGHT_024046.jpg
This document appears to be page 35 of a confidential investment memorandum for a fund named NLV-III (likely New Leaf Venture Partners). It outlines the fund's track record with previous investments (NLV-II) in companies like Array, Acadia, and Intercept Pharmaceuticals, highlighting successful exit multiples. The text details the investment thesis for NLV-III, focusing on targeted biopharmaceutical therapies and biomarker-guided programs that benefit patients, physicians, payers, and pharmaceutical companies. The document bears a House Oversight Committee stamp.
HOUSE_OVERSIGHT_024045.jpg
This document is a confidential investment report page (marked House Oversight) detailing the track record of New Leaf Ventures (NLV) in the biopharmaceutical sector. It highlights their investment strategy, networking capabilities, and specific performance metrics (multiples on invested capital) for various portfolio companies across funds NLV-I, NLV-II, and Sprout Funds. The text lists specific exits and IPOs occurring between 2011 and 2013.
HOUSE_OVERSIGHT_024044.jpg
This document is page 33 of a confidential investment memorandum for a fund named 'New Leaf' (likely New Leaf Venture Partners). It details the fund's strategy regarding late-stage commercialization and small-cap public biotech companies, citing specific successful exits like Acadia Pharmaceuticals (2.5x) and InterCept Pharmaceuticals (3.2x), as well as a recapitalization of MEI Pharma. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was obtained during a congressional investigation, likely into financial networks connected to the broader Epstein inquiry.
HOUSE_OVERSIGHT_024042.jpg
This document is page 31 of a confidential investment strategy memorandum for New Leaf Venture Partners' third fund (NLV-III). It outlines the fund's strategy to invest in 24-28 companies, primarily in the U.S., with a 50-60% allocation focus on Biopharmaceuticals, alongside Information Convergence and Medical Devices. The document bears a House Oversight Bates stamp, indicating it was obtained as part of a congressional investigation, likely regarding financial connections.
HOUSE_OVERSIGHT_024035.jpg
This document appears to be page 24 of a confidential investment memorandum for a fund named 'NLV-III'. It outlines the 'Opportunity in the Healthcare Sector,' citing macro-economic factors such as aging populations, outpacing GDP growth, and emerging market expansion (BRICs) as justifications for investment in healthcare technology. The document bears a House Oversight Bates stamp, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024034.jpg
This document is page 23 of a confidential financial report (Control Number 257) marked with a House Oversight Bates stamp. It details the investment performance of New Leaf Ventures (I and II) and Sprout Funds in two sectors: Medical Devices and Tools, Diagnostics, & Infrastructure, as of March 31, 2014. The report lists aggregate costs, realized values, and internal rates of return (IRR) for these funds.
HOUSE_OVERSIGHT_024033.jpg
This document is a confidential financial report summarizing the investment performance of New Leaf Ventures and Sprout Funds by sector as of March 31, 2014. It details performance metrics (Gross Value, Multiple, and IRR) for Biopharmaceutical and Information Convergence investments across multiple funds dating back to 1993. The document carries a House Oversight Committee stamp, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024030.jpg
This document is a confidential financial report page detailing the performance of two funds, New Leaf Ventures I (NLV-I) and New Leaf Ventures II (NLV-II), as of March 31, 2014. It highlights that both funds are performing in the top quartile according to Cambridge Associates and outlines their capital commitments ($310M and $450M respectively), Internal Rates of Return (IRR), and outperformance against major public indices like the S&P 500. The document bears a House Oversight stamp, suggesting it was obtained during a congressional investigation, likely regarding entities holding these investments.
HOUSE_OVERSIGHT_024020.jpg
This document appears to be page 9 of a confidential investment memorandum or prospectus for 'New Leaf,' a venture capital firm specializing in healthcare technology. The text outlines their deal flow process and distinctive features, highlighting over $1.6 billion in invested capital across six funds and a track record of outperforming market indices. The document bears a House Oversight Committee stamp, suggesting it was submitted as evidence in a congressional investigation.
HOUSE_OVERSIGHT_024019.jpg
This document appears to be page 8 of a confidential investment memorandum for a fund identified as NLV-III (likely New Leaf Ventures III). It outlines the fund's investment strategy regarding Healthcare Information Technology (HIT), Medical Devices, and Biological Research Tools. The text discusses the impact of the HITECH Act and government funding on the market, arguing that regulatory challenges in medical devices will lead the fund to focus on later-stage opportunities, while highlighting the potential of smaller companies in HIT and research tools. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a congressional investigation.
HOUSE_OVERSIGHT_024017.jpg
This document is page 6 of a confidential investment memorandum for New Leaf Ventures III (NLV-III). It outlines the fund's investment strategy, which focuses primarily on the Biopharmaceutical and Information Convergence sectors in the U.S., with a specific emphasis on targeted therapeutics and molecular mechanisms. The document highlights favorable market conditions and a cooperative regulatory environment with the FDA as key drivers for the fund's potential success.
HOUSE_OVERSIGHT_024013.jpg
This document appears to be page 2 of a confidential investment memorandum or prospectus for 'New Leaf' (NLV) funds, specifically discussing the transition of Jim Niedel to Venture Partner for the NLV-III fund. It highlights the 'Long Term Track Record' of the fund managers, noting they have invested over $1.6 billion since 1995 through NLV and Sprout Capital funds, consistently outperforming benchmarks like Cambridge Associates. The document bears a House Oversight Committee stamp, suggesting it was part of a congressional investigation.
HOUSE_OVERSIGHT_024108.jpg
This document is Appendix 5 (Endnotes) of a confidential financial report dated as of March 31, 2014, obtained by the House Oversight Committee (Bates stamp HOUSE_OVERSIGHT_024108). It outlines the methodology for financial performance reporting for funds identified as NLV-I, NLV-II, and the Sprout Funds, distinguishing between 'gross' and 'net' performance and providing legal disclaimers regarding valuations and future results. The document defines the roles of generic 'Fund Managers' and the 'Sprout Group' in managing these investments.
HOUSE_OVERSIGHT_024079.jpg
This document appears to be page 68 of a confidential legal or financial agreement, likely a Private Placement Memorandum (PPM) for an investment fund. It outlines various risks to investors, including the potential for the Fund's assets to be seized to satisfy liabilities, litigation risks, and broad indemnification clauses protecting the General Partner and managers. It explicitly states that Limited Partners (investors) generally have no right to withdraw from the Fund and may be required to return previous financial distributions to cover indemnification obligations. The document bears a House Oversight Committee Bates stamp.
HOUSE_OVERSIGHT_024077.jpg
This document appears to be page 66 of a confidential Private Placement Memorandum or Partnership Agreement describing risk factors for a private equity or hedge fund. It details risks related to financial reserves, conflicts of interest among diverse investors, penalties for failing to meet capital calls, and investment dilution. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was obtained during a congressional investigation, likely related to financial institutions connected to Epstein.
HOUSE_OVERSIGHT_024076.jpg
This document appears to be page 65 of a confidential offering memorandum or similar financial disclosure document for an investment fund. It details specific risk factors and strategies, including leverage risks, investments in public companies, hedging techniques (specifically 'selling short against the box'), portfolio trading policies, and risks associated with non-U.S. investments. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it is part of a congressional investigation.
HOUSE_OVERSIGHT_024074.jpg
This document appears to be page 63 of a confidential Private Placement Memorandum or Offering Memorandum describing risk factors for an investment fund. It details the lack of control Limited Partners have over management, reliance on the General Partner and Fund Managers, and potential conflicts of interest arising from the managers' involvement with other entities like 'Sprout Funds,' 'NLV-I,' and 'NLV-II.' The document bears a House Oversight control number, suggesting it was produced during a congressional investigation.
HOUSE_OVERSIGHT_024073.jpg
This document is page 62 of a confidential offering memorandum (likely a Private Placement Memorandum) for a fund identified as 'NLV-III'. It outlines significant risk factors for potential investors, including the illiquidity of investments, the lack of operating history for the newly formed Fund and General Partner, the lack of assurance regarding profits or distributions, and the highly competitive nature of venture capital investments. The document bears a House Oversight Committee stamp, indicating it is part of a congressional investigation.
| Date | Type | From | To | Amount | Description | Actions |
|---|---|---|---|---|---|---|
| 2014-03-31 | Paid | Fund Managers | Information Conve... | $142,000,000.00 | Total capital invested in 17 investments in the... | View |
| 2014-03-31 | Received | Calvert Investments | Fund Managers | $262,000,000.00 | Combined gross realizations from nine realized ... | View |
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity